Long-term therapeutic strategies in HIV

被引:8
作者
Miles, SA
机构
[1] University of California, Los Angeles, Center for Clinical AIDS Research and Education (CARE), Los Angeles, CA
[2] Clinical AIDS Research and Education (CARE) Clinic, University of California, Los Angeles, Los Angeles, CA 90095-1793
来源
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY | 1997年 / 16卷
关键词
antiretroviral therapy; HIV; AIDS; nucleoside analogues; non-nucleoside analogues; protease inhibition; cytokines; fatigue; oncology model;
D O I
10.1097/00042560-199701001-00006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Advances in the management of human immunodeficiency virus (HIV) disease, including the use of potent combination antiretroviral regimens, has greatly improved the outlook for patients with AIDS. Because HIV patients can now survive for extended periods, clinicians need to develop rational plans for long-term therapy that recognize the impact of such therapy on the patient. There are many similarities between cancer and HIV disease and an oncologic model can be used to design treatment plans for HIV. A successful plan fur long-term management of HIV involves establishing the diagnosis and extent of disease; determining the concerns of the patient as they relate to specific life goals and quality-of-life issues; identifying antiretroviral regimens for initial therapy, salvage therapy: and terminal or experimental therapy; and implementing the plan using clear parameters to evaluate the response to therapy. Tremendous strides have been made in managing HIV disease. It is now time to advance our management of the patients' concerns.
引用
收藏
页码:S36 / S41
页数:6
相关论文
共 25 条
[1]   Protease inhibitors for HIV infection [J].
Bartlett, JG .
ANNALS OF INTERNAL MEDICINE, 1996, 124 (12) :1086-1088
[2]   Antiretroviral therapy for HIV infection in 1996 - Recommendations of an international panel [J].
Carpenter, CCJ ;
Fischl, MA ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (02) :146-154
[3]   COMBINATION THERAPY WITH ZIDOVUDINE AND DIDANOSINE COMPARED WITH ZIDOVUDINE ALONE IN HIV-1 INFECTION [J].
COLLIER, AC ;
COOMBS, RW ;
FISCHL, MA ;
SKOLNIK, PR ;
NORTHFELT, D ;
BOUTIN, P ;
HOOPER, CJ ;
KAPLAN, LD ;
VOLBERDING, PA ;
DAVIS, LG ;
HENRARD, DR ;
WELLER, S ;
COREY, L .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (08) :786-793
[4]   IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS [J].
CONDRA, JH ;
SCHLEIF, WA ;
BLAHY, OM ;
GABRYELSKI, LJ ;
GRAHAM, DJ ;
QUINTERO, JC ;
RHODES, A ;
ROBBINS, HL ;
ROTH, E ;
SHIVAPRAKASH, M ;
TITUS, D ;
YANG, T ;
TEPPLER, H ;
SQUIRES, KE ;
DEUTSCH, PJ ;
EMINI, EA .
NATURE, 1995, 374 (6522) :569-571
[5]   Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection [J].
Coombs, RW ;
Welles, SL ;
Hooper, C ;
Reichelderfer, PS ;
DAquila, RT ;
Japour, AJ ;
Johnson, VA ;
Kuritzkes, DR ;
Richman, DD ;
Kwok, S ;
Todd, J ;
Jackson, JB ;
DeGruttola, V ;
Crumpacker, CS ;
Kahn, J .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (04) :704-712
[6]   Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection - A randomized, double-blind, placebo-controlled trial [J].
DAquila, RT ;
Hughes, MD ;
Johnson, VA ;
Fischl, MA ;
Sommadossi, JP ;
Liou, SH ;
Timpone, J ;
Myers, M ;
Basgoz, N ;
Niu, M ;
Hirsch, MS ;
Costanzo, L ;
Ruben, S ;
Berzins, B ;
Martinez, A ;
Fishman, I ;
Kazial, K ;
Cort, SN ;
Robinson, P ;
Hall, D ;
Macy, H ;
McLaren, C ;
Rooney, J ;
Warwick, J ;
CavailleColl, M ;
Valentine, F ;
Booth, D ;
Soeiro, R ;
Stein, D ;
Zingman, B ;
Schliosberg, J ;
Polsky, B ;
Sepkowitz, K ;
Sharpe, V ;
Giordano, M ;
Wanke, C ;
Gulick, R ;
Craven, D ;
Grodman, C ;
Fife, K ;
Black, J ;
Todd, K ;
Nixon, H ;
Sperber, K ;
Gerits, P ;
Mildvan, D ;
Nicholas, P ;
Murphy, RL ;
Kessler, H ;
Pulvirenti, J .
ANNALS OF INTERNAL MEDICINE, 1996, 124 (12) :1019-1030
[7]  
Devita Vincent T. Jr., 1997, P333
[8]   TREATMENT WITH LAMIVUDINE, ZIDOVUDINE, OR BOTH IN HIV-POSITIVE PATIENTS WITH 200 TO 500 CD4+ CELLS PER CUBIC MILLIMETER [J].
ERON, JJ ;
BENOIT, SL ;
JEMSEK, J ;
MACARTHUR, RD ;
SANTANA, J ;
QUINN, JB ;
KURITZKES, DR ;
FALLON, MA ;
RUBIN, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) :1662-1669
[9]  
GAZZARD B, 1996, P 3 C RETR OPP INF, pLBA5
[10]  
GULICK R, 1996, 3 C RETR OPP INF WAS, pLB7